Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessandra Carè is active.

Publication


Featured researches published by Alessandra Carè.


Molecular and Cellular Biology | 1996

HOXB7 constitutively activates basic fibroblast growth factor in melanomas.

Alessandra Carè; Anna Silvani; Ettore Meccia; Gianfranco Mattia; Antonella Stoppacciaro; G. Parmiani; Cesare Peschle; Mario P. Colombo

Homeobox (HOX) genes control axial specification during mammalian development and also regulate skin morphogenesis. Although selected HOX genes are variably expressed in leukemias and kidney and colon cancer cell lines, their relationship with the neoplastic phenotype remains unclear. In both normal development and neoplastic transformation, HOX target genes are largely unknown. We investigated the expression and function of HOXB cluster genes in human melanoma. The HOXB7 gene was constitutively expressed in all 25 melanoma cell lines and analyzed under both normal and serum-starved conditions, as well as in in vivo primary and metastatic melanoma cells; conversely, HOXB7 was expressed in proliferating but not quiescent normal melanocytes. Treatment of melanoma cell lines with antisense oligomers targeting HOXB7 mRNA markedly inhibited cell proliferation and specifically abolished expression of basic fibroblast growth factor (bFGF) mRNA. Band shift and cotransfection experiments showed that HOXB7 directly transactivates the hFGF gene through one out of five putative homeodomain binding sites present in its promoter. These novel findings indicate a key role for constitutive HOXB7 expression in melanoma cell proliferation via bFGF. The results also raise the possibility that growth factor genes are critical HOX target genes in other developmental and/or neoplastic cell systems.


International Journal of Cancer | 2009

Caveolin-1 tumor-promoting role in human melanoma

Federica Felicetti; Isabella Parolini; Lisabianca Bottero; Katia Fecchi; Maria Cristina Errico; Carla Raggi; Mauro Biffoni; Francesca Spadaro; Michael P. Lisanti; Massimo Sargiacomo; Alessandra Carè

Caveolin‐1 (Cav‐1), a member of the caveolin family, regulates caveolae‐associated signaling proteins, which are involved in many biological processes, including cancer development. Cav‐1 was found to exert a complex and ambiguous role as oncogene or tumor suppressor depending on the cellular microenvironment. Here we investigated Cav‐1 expression and function in a panel of melanomas, finding its expression in all the cell lines. The exception was the primary vertical melanoma cell line, WM983A, characterized by the lack of Cav‐1, and then utilized as a recipient for Cav‐1 gene transduction to address a series of functional studies. The alleged yet controversial role of phospho (Ph)‐Cav‐1 on cell regulation was also tested by transducing the nonphosphorylatable Cav‐1Y14A mutant. Wild‐type Cav‐1, but not mutated Cav‐1Y14A, increased tumorigenicity as indicated by enhanced proliferation, migration, invasion and capacity of forming foci in semisolid medium. Accordingly, Cav‐1 silencing inhibited melanoma cell growth reducing some of the typical traits of malignancy. Finally, we detected a secreted fraction of Cav‐1 associated with cell released microvesicular particles able to stimulate in vitro anchorage independence, migration and invasion in a paracrine/autocrine fashion and, more important, competent to convey metastatic asset from the donor melanoma to the less aggressive recipient cell line. A direct correlation between Cav‐1 levels, the amount of microvesicles released in the culture medium and MMP‐9 expression was also observed.


Oncogene | 1998

Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence

Alessandra Carè; Anna Silvani; Ettore Meccia; Gianfranco Mattia; Cesare Peschle; Mario P. Colombo

Several melanomas, carcinomas, glioblastomas and leukemias showed coordinated expression of HOXB7 and bFGF with exception of the SkBr3 mammary carcinoma that was negative for both. Transduction of HOXB7 gene into SkBr3 cells, induced bFGF expression, increased growth rate, independence from serum withdrawal and ability to form colonies in semisolid medium. ELISA assay showed that most of bFGF was associated to cell lysate when cells were cultured at 1% serum whereas in cells kept to 10% serum bFGF was detected both within cell lysate or secreted into cell supernatants. Antisense oligos to bFGF inhibited the growth of cells cultured in 1%, indicating that beside the possible activation of additional genes other than bFGF by HOXB7 transduction, only bFGF induction accounts for the observed results. Moreover, since inhibition of cell proliferation occurred in cells kept in 1% but not 10% serum, a bFGF intracrine loop appears operative in serum starved SkBr3/HOXB7 cells. Also, these results further indicate bFGF as target of HOXB7.


International Journal of Developmental Neuroscience | 1995

Cytokine regulation of astrocyte function: in-vitro studies using cells from the human brain.

Giobanna Borsellino; Alessandra Carè; Ugo Testa; Paolo Gallo; Giobanni Russo; Cesare Peschle; Giulio Levi

Participation of astrocytes in central nervous system pathophysiology is likely to involve cytokines, both as stimulators and mediators of astrocyte function. We have used highly enriched human astrocyte cultures as an experimental tool to investigate the influence of cytokines on adhesion molecule expression and synthesis of mediators that are probably important in immune and inflammatory reactions involving the nervous system and in cerebral tissue repair. The response of astrocytes to interferon‐γ mainly resulted in increased expression of major histocompatibility complex antigens and co‐stimulatory molecules (intercellular adhesion molecule‐1, LFA‐1α) which mediate astrocyte‐T‐cell interactions. Another co‐stimulatory molecule, B7, was neither expressed nor inducible by IFN‐γ and other cytokines. TNF‐α and IL‐1β were more efficient in stimulating synthesis of immunoregulatory and proinflammatory cytokines (IL‐6, IL‐8 and colony‐stimulating factors), cytokine antagonists (TNF‐α soluble receptors), or cytokines with a possible neuroprotective role (leukemia inhibitory factor); they also increased expression of some co‐stimulatory molecules (intercellular adhesion molecule‐1 and vascular cell adhesion molecule‐1). Transforming growth factor‐β1 was a strong inducer of leukemia inhibitory factor, but did not affect either major histocompatibility complex/co‐stimulatory molecule expression or cytokine synthesis. Thus, different cytokines activate distinct functional programs in astrocytes, which may play a specific role in different brain diseases or at different stages of the same disease. It was additionally observed that the response of human astrocytes to cytokines (in particular the inducible synthesis of certain cytokines) varied greatly depending on the presence or absence of neurons in the culture system. This finding suggests that neuronal‐glial interactions may be implicated in determining the activation threshold of astrocytes to inflammatory cytokines.


Human Molecular Genetics | 2014

Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis

Elisabetta Flex; Mamta Jaiswal; Francesca Pantaleoni; Simone Martinelli; Marion Strullu; Eyad Kalawy Fansa; Aurélie Caye; Alessandro De Luca; Francesca Lepri; Radovan Dvorsky; Luca Pannone; Stefano Paolacci; Si Cai Zhang; Valentina Fodale; Gianfranco Bocchinfuso; Cesare Rossi; Emma M M Burkitt-Wright; Andrea Farrotti; Emilia Stellacci; Serena Cecchetti; Rosangela Ferese; Lisabianca Bottero; Silvana Castro; Odile Fenneteau; Benoît Brethon; Massimo Sanchez; Amy E. Roberts; Helger G. Yntema; Ineke van der Burgt; Paola Cianci

RASopathies, a family of disorders characterized by cardiac defects, defective growth, facial dysmorphism, variable cognitive deficits and predisposition to certain malignancies, are caused by constitutional dysregulation of RAS signalling predominantly through the RAF/MEK/ERK (MAPK) cascade. We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy. We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia. Two of the three identified mutations affected known oncogenic hotspots of RAS genes and conferred variably enhanced RRAS function and stimulus-dependent MAPK activation. Expression of an RRAS mutant homolog in Caenorhabditis elegans enhanced RAS signalling and engendered protruding vulva, a phenotype previously linked to the RASopathy-causing SHOC2S2G mutant. Overall, these findings provide evidence of a functional link between RRAS and MAPK signalling and reveal an unpredicted role of enhanced RRAS function in human disease.


Expert Review of Anticancer Therapy | 2008

MicroRNA-221 and -222 pathway controls melanoma progression.

Federica Felicetti; M. Cristina Errico; Patrizia Segnalini; Gianfranco Mattia; Alessandra Carè

MicroRNAs (miRNAs) represent a new family of small noncoding RNAs that negatively regulate gene expression. Recent studies demonstrated miRNA involvement in all the main biological processes, including tumor development as a consequence of an aberrant deregulated expression. Growing evidence is showing the capability of miRNA expression profiles to unequivocally distinguish between normal and neoplastic tissues, leading to the identification of new diagnostic and/or prognostic molecular markers. In addition, miRNAs might eventually represent new targets to aim at as innovative therapeutic approaches, particularly relevant in those types of cancer, such as melanoma, which are still lacking effective traditional therapies. In particular, the inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting.


PLOS ONE | 2013

miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma

Nadia Felli; Federica Felicetti; Anna Maria Lustri; M. Cristina Errico; Lisabianca Bottero; Alessio Cannistraci; Alessandra De Feo; Marina Petrini; Francesca Pedini; Mauro Biffoni; Ester Alvino; Massimo Negrini; Manuela Ferracin; Gianfranco Mattia; Alessandra Carè

The abnormal expression of several microRNAs has a causal role in tumorigenesis with either antineoplastic or oncogenic functions. Here we demonstrated that miR-126 and miR-126* play a tumor suppressor role in human melanoma through the direct or indirect repression of several key oncogenic molecules. The expression levels of miR-126&126* were elevated in normal melanocytes and primary melanoma cell lines, whereas they markedly declined in metastatic cells. Indeed, the restored expression of miR-126&126* in two advanced melanoma cell lines was accompanied by a significant reduction of proliferation, invasion and chemotaxis in vitro as well as of growth and dissemination in vivo. In accordance, the reverse functional effects were obtained by knocking down miR-126&126* by transfecting antisense LNA oligonucleotides in melanoma cells. Looking for the effectors of these antineoplastic functions, we identified ADAM9 and MMP7, two metalloproteases playing a pivotal role in melanoma progression, as direct targets of miR-126&126*. In addition, as ADAM9 and MMP7 share a role in the proteolytic cleavage of the HB-EGF precursor, we looked for the effectiveness of this regulatory pathway in melanoma, confirming the decrease of HB-EGF activation as a consequence of miR-126&126*-dependent downmodulation of ADAM9 and MMP7. Finally, gene profile analyses showed that miR-126&126* reexpression was sufficient to inactivate other key signaling pathways involved in the oncogenic transformation, as PI3K/AKT and MAPK, and to restore melanogenesis, as indicated by KIT/MITF/TYR induction. In view of this miR-126&126* wide-ranging action, we believe that the replacement of these microRNAs might be considered a promising therapeutic approach.


Oncogene | 2004

Role of PLZF in melanoma progression

Federica Felicetti; Lisabianca Bottero; Nadia Felli; Gianfranco Mattia; Catherine Labbaye; Ester Alvino; Cesare Peschle; Mario P. Colombo; Alessandra Carè

The promyelocytic leukemia zinc finger (PLZF) protein has been described as a transcriptional repressor of homeobox (HOX)-containing genes during embryogenesis. As we previously demonstrated a functional link between overexpression of HOXB7 and melanoma progression, we investigated the lack of PLZF as the possible cause of HOXB7 constitutive activation in these neoplastic cells. Accordingly, we found PLZF expression in melanocytes, but not in melanoma cells, a pattern inversely related to that of HOXB7. PLZF retroviral gene transduction was then performed in a panel of melanoma cell lines, and tumorigenicity was compared with that of empty vector-transduced control cell lines. Evaluation of in vitro migration, invasion and adhesion indicated that PLZF gene transduction induced a less malignant phenotype, as confirmed through in vivo studies performed in athymic nude mice. This reduced tumorigenicity was not coupled with HOXB7 repression. In order to find more about the molecular targets of PLZF, the gene expression profiles of PLZF- and empty vector-transduced A375 melanoma cells were analysed by Atlas Cancer macroarray. Among several genes modulated by PLZF enforced expression, of particular interest were integrin αvβ3, osteonectin/SPARC and matrix metalloprotease-9 that were downmodulated, and the tyrosinase-related protein-1 that was upregulated in all the analysed samples. This profile confirms the reduced tumorigenic phenotype with reversion to a more differentiated, melanocyte like, pattern, thus suggesting a suppressor role for PLZF in solid tumors. Moreover, these results indicate that PLZF and HOXB7 are functionally independent and that their coupled deregulation may account for most of the alterations described in melanomas.


Oncogene | 1999

Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation.

Alessandra Carè; Mauro Valtieri; Gianfranco Mattia; Ettore Meccia; Barbara Masella; Luisella Luchetti; Federica Felicetti; Mario P. Colombo; Cesare Peschle

Hematopoietic progenitor/stem cells (HPCs/HSCs) purified from human adult peripheral blood (PB) were triggered into cycling, retrovirally transduced with HOXB7 and then functionally assayed in vitro. HPCs were assayed in multi- and unilineage differentiation cultures in either liquid phase or semisolid medium, primitive HPCs in the high proliferative potential colony-forming cell (HPP – CFC) evaluation system and putative HSCs in Dexter type long-term culture (LTC) as LTC initiating cells (LTC – ICs). Control experiments ensured that the exogenous HOXB7 gene was constantly expressed, while the endogenous one was barely or not transcribed. Enforced expression of the gene markedly modulated the proliferation/differentiation program of the entire HSC/HPC population. Enforced HOXB7 expression exerted a potent stimulatory effect on the proliferation of the primitive HPC and putative HSC subsets, assayed as HPP – CFCs and LTC – ICs respectively. While not modifying the total number of HPCs, exogenous HOXB7 induced an increase of the number of granulo-monocytic (GM) HPCs [colony-forming unit GM (CFU – GM) CFU – GM, CFU-G and CFU-M, as evaluated by clonogenic assays] and markedly amplified the progeny of both CFU-G and CFU-M, which showed a sustained proliferation through at least 1 – 2 months (as evaluated in liquid suspension culture). The prolonged proliferative stimulus induced by HOXB7 transfer into LTC, primitive and GM oriented HPC culture was characterized by persistent proliferation of a discrete population of blast cells and a large pool of differentiated myeloid precursors. Altogether, these results suggest the hypothesis that the proliferative stimulus exerted by exogenous HOXB7 in primitive and GM-oriented HPCs may represent a preleukemic immortalization step. Consistent with the functional role of HOXB7 in the initial ontogenetic phase, these studies indicate that ectopic HOXB7 expression in early HPCs and HSCs from adult PB stimulates their self renewal, sustained proliferation and myeloid differentiation.


European Journal of Immunology | 2010

A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2

Silvia Piconese; Paola Pittoni; Alessia Burocchi; Andrea Gorzanelli; Alessandra Carè; Claudio Tripodo; Mario P. Colombo

OX40 stimulation is known to enhance activation of effector T cells and to inhibit induction and suppressive function of Treg. Here we uncovered a novel role of OX40 in sustaining Treg competitive fitness in vivo, during repopulation of lymphopenic hosts and reconstitution of BM chimeras. Defective expansion of OX40‐null Treg diminished their ability to suppress inflammation in a model of lymphopenia‐driven colitis. OX40‐mediated promotion of Treg fitness spanned beyond lymphopenic environments, as endogenous Treg in OX40‐null mice showed decreased accumulation during thymic development, enhanced susceptibility to antibody‐mediated depletion and defective turnover following thymectomy. In vitro, OX40‐deficient Treg were found to be intrinsically hyporesponsive to IL‐2, in terms of Stat5 phosphorylation and proliferation, according to elevated SOCS1 content and reduced miR155 expression. Therefore, OX40 is a key factor in shaping Treg sensitivity to IL‐2 and promoting their proliferation and survival, toward accurate immune regulation.

Collaboration


Dive into the Alessandra Carè's collaboration.

Top Co-Authors

Avatar

Cesare Peschle

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Federica Felicetti

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Mario P. Colombo

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Gianfranco Mattia

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Lisabianca Bottero

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Ugo Testa

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Marina Petrini

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Mauro Valtieri

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Nadia Felli

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Ettore Meccia

Istituto Superiore di Sanità

View shared research outputs
Researchain Logo
Decentralizing Knowledge